Table 3.
Multivariable regression analysis of various biomarkers versus FGF19.
| Control | T2DM | HCC | T2DM-HCC | |||||
|---|---|---|---|---|---|---|---|---|
| Standard β | p | Standard β | p | Standard β | p | Standard β | p | |
| Model 1 | ||||||||
| TBA | 0.397 | 0.040 | 0.400 | 0.039 | 0.562 | 0.024 | 0.701 | 0.024 |
| Model 2 | ||||||||
| TBA | 0.414 | 0.031 | 0.461 | 0.032 | 0.637 | 0.037 | 0.826 | 0.044 |
Model 1: crude model without covariate adjustment; model 2: adjustment for age, SBP, FPG, and CEA. Control: healthy control; T2DM: newly diagnosed type 2 diabetes mellitus patients; HCC: newly diagnosed hepatocellular carcinoma patients; T2DM-HCC: type 2 diabetes mellitus combined newly diagnosed hepatocellular carcinoma patients. Abbreviations are same as in Table 1.